Dr. Ulrika Tehler is a Principal Scientist within the Early Product Development, Pharmaceutical Sciences at AstraZeneca in Gothenburg, Sweden. She joined AstraZeneca in 2009 and has since 2011 focused on drug delivery to the lungs. Ulrika pioneered the inhaled dissolution area within AstraZeneca, and has been a major contributor to the development of Lung-SIM, an in silico tool for physiologically based biopharmaceutical predictions for inhaled drug delivery.
Ulrika earned her PhD in organic chemistry from University of Southern California. Prior to joining AstraZeneca, she held academic post-doc positions in the field of pharmaceutical sciences at University of Michigan and Uppsala University. Ulrika is an interdisciplinary scientist renowned for building relationships across departments and delivering results and innovative solutions to projects.
Experimental evidence of regional lung deposition differences effecting the systemic exposure in dog
